Join Growin Stock Community!

Agenus inc.AGEN.US Overview

US StockHealthcare
(No presentation for AGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AGEN AI Insights

AGEN Overall Performance

AGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AGEN Recent Performance

-0.30%

Agenus inc.

0.05%

Avg of Sector

-0.31%

S&P500

AGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AGEN Key Information

AGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AGEN Profile

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Price of AGEN

AGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.13
PB Ratio
218.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
98.93%
Net Margin
-32.92%
Revenue Growth (YoY)
-33.41%
Profit Growth (YoY)
-33.86%
3-Year Revenue Growth
9.91%
3-Year Profit Growth
9.62%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.13
PB Ratio
218.61
Price-to-FCF
-
Gross Margin
98.93%
Net Margin
-32.92%
Revenue Growth (YoY)
-33.41%
Profit Growth (YoY)
-33.86%
3-Year Revenue Growth
9.91%
3-Year Profit Growth
9.62%

  • When is AGEN's latest earnings report released?

    The most recent financial report for Agenus inc. (AGEN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AGEN's short-term business performance and financial health. For the latest updates on AGEN's earnings releases, visit this page regularly.

  • What is the operating profit of AGEN?

    According to the latest financial report, Agenus inc. (AGEN) reported an Operating Profit of -4.86M with an Operating Margin of -16.08% this period, representing a growth of 85.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AGEN's revenue growth?

    In the latest financial report, Agenus inc. (AGEN) announced revenue of 30.24M, with a Year-Over-Year growth rate of 20.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AGEN have?

    As of the end of the reporting period, Agenus inc. (AGEN) had total debt of 45.71M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AGEN have?

    At the end of the period, Agenus inc. (AGEN) held Total Cash and Cash Equivalents of 3.46M, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AGEN go with three margins increasing?

    In the latest report, Agenus inc. (AGEN) did not achieve the “three margins increasing” benchmark, with a gross margin of 97.9%%, operating margin of -16.08%%, and net margin of 211.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AGEN's profit trajectory and future growth potential.

  • Is AGEN's EPS continuing to grow?

    According to the past four quarterly reports, Agenus inc. (AGEN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AGEN?

    Agenus inc. (AGEN)'s Free Cash Flow (FCF) for the period is -14.66M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 72.48% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.